Siena and Rosia

over a century of innovation

1904

Foundation of the Institute

In a small villa on the outskirts of Siena, Achille Sclavo founds the Institute, to produce the serum against anthrax he had discovered.

More

1910-20

The industrial development

The Sclavo Institute is restructured to meet the scientific advances of the time and the needs of World War I.

More

1930-40

Sclavo’s legacy

After the death of the founder, the Institute remained a family business, gradually establishing itself at the national level.

More

1950

The international scope and new applications

The increasing degree of technical sophistication leads the Institute to be a modern center not only of production, but also for the study and research.

More

1960

Albert Sabin’s turning point

The Institute begins to produce Sabin’s anti-polio and starts the collaboration with the Wellcome Foundation in London.

More

1970-80

Expansion of the institute

The Institute extends in the US, while the futuristic Research Center is born and the activities of the new area of Rosia start.

More

1990

The genetics revolution

From the collaboration with Venter, the Reverse Vaccinology technique is born, key of the vaccine against meningococcus B.

More

2000

The fight against meningitis and flu

The company becomes one of the most important realities in vaccines, whose study proceeds, in addition to their use in mass vaccinations.

More

Today

Number one in vaccines

With the integration in GSK, the Siena and Rosia site becomes part of a pharmaceutical company committed on a global scale.

More

 
chiudi

2000

The fight against meningitis and flu


The company becomes one of the most important realities in vaccines, whose study proceeds, in addition to their use in mass vaccinations.

020

– The high security research lab where the meningococcus B vaccine has been studied  –

In 2000 the company contributed to an extensive vaccination campaign in Britain against meningitis type C. In 2001, the vaccine was approved in Italy and, in 2004, it earned the Galen Award.
Genomics had become the new frontier for the study of pathogens, and in 2003 it allowed the mapping of the genome of the coronavirus, responsible for SARS.
In 2004, a vaccine developed specifically against the meningococcus type B, which plagued New Zealand, was used in that Country for a targeted vaccination campaign. The same year saw the discovery of the pili present in streptococcus, meningococcus and pneumococcus.
The Sabin Vaccine Institute conferred the company the “Global Philanthropy Award”.

ParticolareSperlat2_low

– A manufacturing machinery –

In 2006, Novartis acquired Chiron, creating Novartis Vaccines and Diagnostics. In 2008, the Novartis Vaccines Institute for Global Health was inaugurated in Siena, the only institution in the world, with non-profit mission, which is involved in the research and development of vaccines for diseases that predominantly affect the developing Countries, in particular salmonella infections. Located on the campus of Siena, it can benefit from all possible synergies in technology, knowledge and services.

129

– A snap-shot from Novartis “Day One”: Rino Rappuoli (Head of Global Research) introduce the new organization to the associates –

The year 2009 saw the great commitment for the worldwide supply of vaccines against pandemic influenza H1N1: from the first inoculum, made on ​​July 2, the company was able to release the first batch already on October 2 of the same year, producing a total of over 100 million doses.
In 2010 the vaccine against meningococci type A, C, Y and W135 was registered in Europe and the US and, in 2013, that against meningococcus B, an innovative vaccine developed through the Reverse Vaccinology technique, and which in 2014 received the Galen Award.

| Materiale d’archivio gentilmente concesso da Gruppo Anziani Sclavo |